| ANTUNES, Liliana, Clara MAZAGATOS, Iván MARTÍNEZ-BAL, Veronica GOMEZ, Maria-Luise BORG, Goranka PETROVIČ, Roisin DUFFY, Francois E DUFRASNE, Ralf DÜRRWALD, Mihaela LAZAR, Ligita JANCORIENE, Beatrix OROSZI, Petr HUSA and Lenka SOUČKOVÁ. Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023. EUROSURVEILLANCE. STOCKHOLM: EUR CENTRE DIS PREVENTION & CONTROL, 2024, vol. 29, No 3, p. 1-8. ISSN 1560-7917. Available from: https://dx.doi.org/10.2807/1560-7917.ES.2024.29.3.2300708. |
Other formats:
BibTeX
LaTeX
RIS
@article{2364017,
author = {Antunes, Liliana and Mazagatos, Clara and MartínezandBal, Iván and Gomez, Veronica and Borg, MariaandLuise and Petrovič, Goranka and Duffy, Roisin and Dufrasne, Francois E and Dürrwald, Ralf and Lazar, Mihaela and Jancoriene, Ligita and Oroszi, Beatrix and Husa, Petr and Součková, Lenka},
article_location = {STOCKHOLM},
article_number = {3},
doi = {http://dx.doi.org/10.2807/1560-7917.ES.2024.29.3.2300708},
keywords = {bivalent mRNA COVID-19 vaccines;Omicron XBB lineage-predominant period;VEBIS SARI VE network},
language = {eng},
issn = {1560-7917},
journal = {EUROSURVEILLANCE},
title = {Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023},
url = {https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.3.2300708#abstract_content},
volume = {29},
year = {2024}
}
TY - JOUR
ID - 2364017
AU - Antunes, Liliana - Mazagatos, Clara - Martínez-Bal, Iván - Gomez, Veronica - Borg, Maria-Luise - Petrovič, Goranka - Duffy, Roisin - Dufrasne, Francois E - Dürrwald, Ralf - Lazar, Mihaela - Jancoriene, Ligita - Oroszi, Beatrix - Husa, Petr - Součková, Lenka
PY - 2024
TI - Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023
JF - EUROSURVEILLANCE
VL - 29
IS - 3
SP - 1-8
EP - 1-8
PB - EUR CENTRE DIS PREVENTION & CONTROL
SN - 15607917
KW - bivalent mRNA COVID-19 vaccines;Omicron XBB lineage-predominant period;VEBIS SARI VE network
UR - https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.3.2300708#abstract_content
N2 - We conducted a multicentre hospital-based test-negative case–control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14–89 days post-vaccination, 15% (95% CI: −12 to 35) at 90–179 days, and lower to no effect thereafter.
ER -
ANTUNES, Liliana, Clara MAZAGATOS, Iván MARTÍNEZ-BAL, Veronica GOMEZ, Maria-Luise BORG, Goranka PETROVIČ, Roisin DUFFY, Francois E DUFRASNE, Ralf DÜRRWALD, Mihaela LAZAR, Ligita JANCORIENE, Beatrix OROSZI, Petr HUSA and Lenka SOUČKOVÁ. Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023. \textit{EUROSURVEILLANCE}. STOCKHOLM: EUR CENTRE DIS PREVENTION \&{}amp; CONTROL, 2024, vol.~29, No~3, p.~1-8. ISSN~1560-7917. Available from: https://dx.doi.org/10.2807/1560-7917.ES.2024.29.3.2300708.
|
